126170-40-9

Basic information

• Product Name: [(2S,4R)-4-(6-amino-9H-purin-9-yl)oxetan-2-yl]methanol
• Synonyms: 9-((2R,4S)-4-(Hydroxymethyl)-2-oxetanyl)adenine; 9-[(2R,4S)-4-(Hydroxymethyl)-2-oxetanyl]adenine
• CAS NO: 126170-40-9
• Molecular Formula: C₉H₁₁N₅O₂
• Molecular Weight: 221.2159
• Mol File: 126170-40-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 541.4°C at 760 mmHg
• Flash Point: 281.2°C
• Density: 1.88g/cm³
• Vapor Pressure: 1.49E-12mmHg at 25°C
• Refractive Index: 1.876
• CAS DataBase Reference: [(2S,4R)-4-(6-amino-9H-purin-9-yl)oxetan-2-yl]methanol(CAS DataBase Reference)
• NIST Chemistry Reference: [(2S,4R)-4-(6-amino-9H-purin-9-yl)oxetan-2-yl]methanol(126170-40-9)
• EPA Substance Registry System: [(2S,4R)-4-(6-amino-9H-purin-9-yl)oxetan-2-yl]methanol(126170-40-9)

Safety Data

• Hazardous Substances Data: 126170-40-9(Hazardous Substances Data)

Usage

General Description

[(2S,4R)-4-(6-amino-9H-purin-9-yl)oxetan-2-yl]methanol, also known as adenosine, is a nucleoside and a key molecule in many biological processes. It consists of a purine base (adenine) attached to a ribose sugar molecule, with a methyl group and hydroxyl group attached to the ribose. Adenosine plays a critical role in cellular energy transfer as a component of ATP (adenosine triphosphate) and ADP (adenosine diphosphate). It also acts as a neurotransmitter, regulating blood flow, heart function, and neurotransmitter release. Adenosine is also used in medicine as a drug for treating certain heart conditions and as a diagnostic agent for heart imaging.

Upstream product

• 131550-08-8 9-(2,4-O(R)-benzylidene-β-D-threo-oxetanosyl)adenine 
• 230967-28-9 epinoroxetanocin 
• 126170-63-6 N-{9-[(2R,3S,4R)-4-(tert-Butyl-dimethyl-silanyloxymethyl)-3-hydroxy-oxetan-2-yl]-9H-purin-6-yl}-benzamide 
• 126170-68-1 Trifluoro-methanesulfonic acid (2R,3S,4R)-2-(6-benzoylamino-purin-9-yl)-4-(tert-butyl-dimethyl-silanyloxymethyl)-oxetan-3-yl ester 
• 126170-61-4 Methanesulfonic acid (2R,3R,4S)-2-(6-benzoylamino-purin-9-yl)-4-(tert-butyl-dimethyl-silanyloxymethyl)-oxetan-3-ylmethyl ester 
• 126170-64-7 N-{9-[(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxymethyl)-3-oxo-oxetan-2-yl]-9H-purin-6-yl}-benzamide 
• 126170-59-0 N⁶-benzoyl-5'-O-(TBDMS)oxetanocin A 
• 126170-62-5 N-{9-[(2R,4S)-4-(tert-Butyl-dimethyl-silanyloxymethyl)-3-methylene-oxetan-2-yl]-9H-purin-6-yl}-benzamide 
• 126170-66-9 N-{9-[(2R,4S)-4-(tert-Butyl-dimethyl-silanyloxymethyl)-oxetan-2-yl]-9H-purin-6-yl}-benzamide 
• 121885-21-0 Oxetanocin A N⁶-benzoate 

Relevant articles and documents

Reducing dehalogenating method of organic halogenated compound

The invention discloses a reducing dehalogenating method of an organic halogenated compound. The reducing dehalogenating method comprises: mixing an organic halogenated compound R-X, a non-noble metalpromoter, a sulfide and an alkali, and carrying out a reducing dehalogenating reaction to obtain a reducing product R-H, wherein R is at least one selected from alkyl and aryl, and X is at least oneselected from iodine, bromine and chlorine. According to the present invention, the types and the ratio (especially the specific type of the promoter) of various raw materials used in the reducing dehalogenating reaction, the corresponding reaction conditions and the like are researched and improved, such that the problems of use of highly-toxic or expensive reagent, poor tolerance of the group, narrow application range of the substrate and the like in the prior art can be effectively solved.

Synthesis and antiviral activity of oxetanocin derivatives

The sugar part of natural oxetanocin A was chemically modified. Some of the derivatives demonstrated strong antiviral activity against human immunodeficiency virus (HIV).